Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZVRA vs RGNX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ZVRA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)
ZVRA Overall Winner
6-Pillar Tally: ZVRA 5 – 1 RGNX
Matrix Metrics: ZVRA 8 – 2 RGNX
As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZVRA carries a Unified Composite Score of 49.4/100 (HOLD) at $9.21 (9.3x Forward P/E, 31.5% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin).
- Technical & Structure Timing Caution: ZVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ZVRA vs RGNX
ZVRA
Head-to-Head Winner
Zevra Therapeutics, Inc. Common Stock
$9.21
+1.49% 1D
Market Cap
$664.1M
TTM Revenue
$148M
Forward P/E
9.3x
Beta / 30D Vol
1.18β · 95% Vol
Unified Composite Score
49.4
HOLD
Tech 37.0
Fund 53.0
Flow 67.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
RGNX
REGENXBIO Inc.
$7.45
-2.49% 1D
Market Cap
$500.9M
TTM Revenue
$154M
Forward P/E
N/M
Beta / 30D Vol
1.82β · 76% Vol
Unified Composite Score
45.3
HOLD
Tech 36.0
Fund 44.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
6-Pillar Scorecard Institutional Category Breakdown (ZVRA 5 – 1 RGNX)
1. Valuation Multiples
ZVRA
Forward P/E
9.3x
N/M
Trailing P/E
9.7x
N/M
PEG Ratio
10.67x
0.26x
EV / Revenue
3.7x
3.1x
2. Growth & Scale
ZVRA
Revenue Growth (YoY)
+44.9%
-69.2%
Earnings Growth (YoY)
-88.4%
+0.0%
TTM Revenue (USD)
$148M
$154M
Market Cap
$664.1M
$500.9M
3. Profitability & Quality
ZVRA
Gross Margin
95.4%
-64.5%
Operating Margin
31.5%
-120.4%
Net Profit Margin
52.8%
-113.9%
Return on Equity (ROE)
41.9%
-113.2%
4. Balance Sheet & Cash Flow
ZVRA
Cash Generation (TTM)
$38M
-$155M
Cash Flow Margin
25.9%
-100.6%
Net Cash / Leverage
$121M Net Cash
$29M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
RGNX
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
71.7% (14th %ile)
349.6% (52nd %ile)
Put/Call OI Skew
1.62x (Put-Skewed)
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat
ZVRA
OpEx & R&D Intensity
63.9% of Rev ($94M)
55.9% of Rev ($86M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ZVRA (8) vs RGNX (2)| Institutional Metric | ZVRA | RGNX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $664.1M | $500.9M | ZVRA | |
| Trailing P/E Ratio | 9.7x | N/M | ZVRA | |
| Forward P/E Ratio | 9.3x | N/M | ZVRA | |
| Revenue Growth (YoY) | +44.9% | -69.2% | ZVRA | |
| Operating Margin (TTM) | 31.5% | -120.4% | ZVRA | |
| Net Profit Margin | 52.8% | -113.9% | ZVRA | |
| Return on Equity (ROE) | 41.9% | -113.2% | ZVRA | |
| 52-Week Range Position | 17% ($8–$15) | 19% ($5–$16) | RGNX | |
| Beta / 30D Volatility | 1.18β · 95% Vol | 1.82β · 76% Vol | RGNX | |
| Unified Institutional Score | 49.4 / 100 (HOLD) | 45.3 / 100 (HOLD) | ZVRA | |
| Trailing 12M Revenue (USD) | $148M | $154M | Scale | |
| Gross Profit Margin (TTM) | 95.4% | -64.5% | Quality | |
| PEG Ratio & EV / Revenue | 10.67x PEG · 3.7x EV/Rev | 0.26x PEG · 3.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $38M ($121M Net Cash) | -$155M ($29M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
RGNX +14.87 pp
3M Horizon
ZVRA +12.35 pp
6M Horizon
RGNX +43.51 pp
1Y Horizon
ZVRA +35.84 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ZVRA Revenue | RGNX Revenue | ZVRA Op. Margin | RGNX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $220M | N/A | 40.3% | RGNX |
| FY2019 | $10M | $40M | -158.4% | -422.9% | ZVRA |
| FY2020 | $10M | $150M | -42.2% | -77.1% | ZVRA |
| FY2021 | $30M | $470M | 27.0% | 34.0% | RGNX |
| FY2022 | $10M | $110M | -418.9% | -233.2% | RGNX |
| FY2023 | $30M | $90M | -180.6% | -297.1% | ZVRA |
| FY2024 | $20M | $80M | -368.5% | -280.0% | RGNX |
| FY2025 | $110M | $170M | -59.1% | -94.6% | ZVRA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ZVRA
BREAKDOWN
Current IV
71.7%
IV Percentile
14th %ile
Put/Call OI Skew
1.62x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact ZVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
RGNX
BREAKDOWN
Current IV
349.6%
IV Percentile
52nd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ZVRA Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
63.9% of Rev ($94M)
90D Engineering Disclosures
0 Published
RGNX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
55.9% of Rev ($86M)
90D Engineering Disclosures
0 Published
Investor FAQ ZVRA vs RGNX Key Questions & Quantitative Answers
As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZVRA carries a Unified Composite Score of 49.4/100 (HOLD) at $9.21 (9.3x Forward P/E, 31.5% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin). Technical & Structure Timing Caution: ZVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ZVRA leads the Growth & Scale pillar: ZVRA posts +44.9% YoY revenue growth and -88.4% YoY earnings growth on $148M TTM revenue (95.4% gross margin, 31.5% operating margin), compared with RGNX at -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ZVRA cumulative revenue shifted +1000.0% while RGNX shifted -22.7%. In operating R&D and SG&A reinvestment, ZVRA deploys 63.9% of Rev ($94M) (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($86M) (0 disclosures) for RGNX.
ZVRA screens cheaper on headline valuation multiples. ZVRA trades at 9.3x Forward P/E, 9.7x Trailing P/E, 10.67x PEG, and 3.7x EV/Revenue (25.9% FCF margin), whereas RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZVRA (41.9% ROE) versus RGNX (-113.2% ROE) capital efficiency.
In options market volatility and institutional positioning, ZVRA carries 71.7% implied volatility (14th %ile, Compressed (<25th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.18β · 95% Vol realized risk). By comparison, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
RGNX vs ZVRA · Reverse Pair
ZVRA vs ADUR
· Sector Peer
ZVRA vs MLYS
· Sector Peer
ZVRA vs GLUE
· Sector Peer
RGNX vs QURE
· Sector Peer
RGNX vs MGTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem